Index

3ie initiative 196

A Guide to Social Return on Investment 67
Aassve, A. 440–41
Abraham, J. 303, 305, 307, 309, 312–13, 314
absolute evaluation 60
accelerated approval processes 312–13
accountability 8, 254–5, 288, 416
challenges to demonstrating effectiveness 189–95, 198–9
demonstration frameworks 183, 185
and impact of social programmes 184–9
increased demands for 183, 184–5, 198
and public-sector reforms 461
and randomized controlled trials 25
and social impact value chain 185–7, 191
and transparency 183, 184
accreditation 4
ACF (advocacy coalition framework) 149
‘Achieving Better Community Development’ 122
Achilles, C. 23
active citizenship 389, 391, 399
active involvement of groups (participatory evaluation feature) 120–22
active social policy 161–2, 166, 168–70, 173, 175
active use benefits/impacts 80
addictive behaviour 83–4
ADLs (activities of daily living) 324
advanced economies, evaluation in 166, 168–9, 171
Advancing Quality initiative 291

after-school program study 17–20
aggregate net benefits 92
AidGrade 196
AIDS crisis 312
Ainsworth, D. 268–9, 271
AIS (American Spinal Injury Association Impairment Scale) 91
Akgunduz, Y.E. 439, 445–6
allocative efficiency 77, 87, 89
ALMPs (active labour-market policies) 2, 162, 345, 360
activating 356–7
advanced economy evaluations 166, 168–9
caseload factors 357–60
effectiveness of 345, 347, 353–4, 355–6, 357–60
evaluation of 351–3
impact on aggregate employment/unemployment 355–6
labour market institutions and reforms 346, 347–8, 354, 360
microeconomic evidence 353–4
and social impact bonds 266–7, 270
‘use’ and ‘misuse’ of evaluation, 172
see also employment/unemployment; labour market
American Institutes for Research 25
American Spinal Injury Association 91
ANCOVA (analysis of covariance) 48
ANOVA (analysis of variance) 30
anti-stigma campaigns 294–5
‘apples and oranges’ problem 113
Arni, P. 357
Arrow, K.J. 86
Asai, Y. 439–40
Asante, A. 290
ASCOT (QoL instrument) 333, 334, 335, 336, 337–8
assimilation 383
AstraZeneca 313
asylums 295–6
Handbook of social policy evaluation

ATOS Healthcare 212, 214, 368, 372, 374, 377
attention points 236–7, 456, 457, 459, 460–69
‘attribution problem’ of interventions 518
auditing 4
austerity policies 203, 209–11, 213–14, 219, 263–4, 272, 368, 378, 450
‘authoritarian liberalism’ 175–6

Bacchi, Carol 176
Baio, G. 90
Baker, M. 440
Balanced Scorecard 190
Bambra, C. 214, 215
Banerjee, Abhijit V. 164–5
Banks, G. 142
Bartley, M. 147
Bassanini, A. 347
Baudrillard, Jean 494, 496–8, 500, 501–3, 508–9, 512
Baumberg, B. 215, 216, 217, 377, 379
Baumgartner, F.R. 149
BCR (benefit–cost ratio) 85
Beatty, C. 209, 212
bed net programmes 187, 190
Beem, Christopher 168
behavioural engineering 161
belief in benefits of participation
(participatory evaluation feature) 120, 124–6, 127, 128–30
benchmarking 395, 423, 482
‘benefit allocation’ 204, 210
benefit sanctions 364, 366, 367, 368, 375
‘benefit/welfare dependency’ 168, 346, 366
Berton, F. 349
best evidence, defining 3–6
best practice 250, 252, 255, 411, 413–14, 415, 419, 511, 516
beta interferon 310
Bettendorf, L.J. 445, 446
Bevir, M. 206
Beyondblue campaign 294
bias
and evaluation of medicine 305–6, 312, 313–14, 316, 317
and evidence-based policy-making 248, 256, 259
and participatory evaluation 134–5
pre-treatment heterogeneity bias 42
and quasi-experiments 40–41, 42–3, 44–5, 46, 47, 48, 52–3, 189
and randomized controlled trials 15, 16, 18–19, 20, 23, 248, 285
selection bias 18, 41, 45, 46, 52, 116, 189, 285, 518
and systematic reviews 101–2, 105, 107, 108, 116
big data 3, 132, 516
Bill and Melinda Gates Foundation 185
‘bio’ mapping projects 131–2
bird surveys 126
‘black box’ approach 269
Black, Carol 212
Blair, Tony 503
Blanchard, O. 346, 349
‘blue-skies’ thinking 155
Blunkett, David 151
Boardman, A.E. 86
Boehm, A. 399
Bohr, Niels 495–6
Bolderson, H. 272
Bolsa Familia programme 165
Boockmann, B. 349–50
Boolean strategies 107
Boruch, R. 16, 24, 25–6, 27, 33
‘bottom-up’ approaches 423
brands/branding 498–9
Brooks-Gun, J. 440
Brown, P. 309
Bruns, B. 23
Bryk, A. 27, 29
Burgess, R. 215
Byrne, D. 204, 205, 219
CAB (Citizens Advice Bureau) 371, 372–3
calculating the SROI (SROI stage) 68, 70, 72
Caliendo, M. 42
Callaghan, L. 337
Campbell Collaboration 24, 101
Campbell Institute 468
Campbell, D.T. 16–17

Downloaded from https://www.elgaronline.com/ at 11/01/2023 08:29:22AM via free access
Canadian Institutes of Health Research 142

capability approach 327–8
‘capacity for choice’ 328
Caplan, N. 146
Card, D. 353, 354
Carneiro, P. 440
Carpenter, D. 311
cash-for-care benefits 325
Castelli, A. 209
Castro, Fidel 317, 318
CAT (Customer Assessment Tool) 370
‘catastrophic’ costs/losses 287, 289, 292
causal intervention effects 38, 39, 42, 43
causal treatment effects 40–41
CBA (cost–benefit analysis)
analysis steps 60–63, 64, 74, 78–85, 94
benchmark of 78
characteristics of 59–65
‘comprehensive’ 81, 86, 87–8, 95, 96
and conditional cash transfer programmes 171
and economic evaluation of policies 77–86, 87–8, 92–6
further directions for quality appraisal 73–4
generalizations 58, 74
‘incomplete’ 81, 86, 87–8, 96
multi-sectoral CBA 94–5
and opportunity costs 62, 83, 84
and performance management 230
and randomized control trials 82
and sensitivity analysis 63, 65, 78, 85
simplified example of 63–5
and social accounting 57–8, 65
and social impact bonds 198
and social return on investment 57–9, 65, 72, 73–5
and social welfare targets 59–60
and stakeholder decisions 58
and stewardship 58
CBN (costs of basic needs) 472, 473
CCGs (clinical commissioning groups) 315
CCR (cross-cutting review) 152
CCTs (conditional cash transfers) 162, 163–6, 167, 170, 173–4, 175, 176
CE (cost/effectiveness) ratios 88–90
CEA (cost-effectiveness analysis)
and cost–benefit analysis 59, 73
and economic evaluation of policies 77, 87, 88–90, 91, 95, 96
and impact of social programmes 183–4
and performance management 230
and randomized controlled trials 26–7
Centre for Management and Policy Studies 151
CESI (Centre for Economic and Social Inclusion) 375–6
change mechanism (programme theory) 404, 406, 408, 413, 415
change score method 48
Charities Evaluation Services 122
Chetty, R. 23, 33–4
child benefits 431, 432–3, 435–8, 483–5, 486, 491
childcare services 431, 433–4, 444–8, 449
Children Centres (Sure Start) 154
children, young people, and family interventions 403–4, 425–6, 431
child benefits 431, 432–3, 435–8, 483–5, 486, 491
childcare services 431, 433–4, 437, 439–40, 444–8, 449
Child Outcomes Research Consortium 403, 416–19, 425, 426
DIY Health project 407–10
and employment 434, 436–7, 438–40, 441, 444–6, 448–9, 450
engaging practitioners, services and policy-makers 419–25
and evidence-based policy-making 403, 405, 419–26
family policy background 432–5
GP attendance 407–10
key recommendations 426
‘Matthew effect’ 433, 436, 441, 449
mean outcomes 431, 434, 435, 440–41, 444, 446, 448, 449, 450
MINDFUL approach 418, 426
multiple objectives of 431, 432, 434–5, 438, 448–9
parental leave schemes 431, 432, 433, 438–44, 446–7, 449
perinatal mental health value
Scorecard 410–15
programme theories 404–6, 407–9, 413, 415, 426
realistic evaluation 404–10, 414, 415, 425–6
researcher–policy maker
relationships 424–5
routine outcome monitoring 415–16, 417–19, 425, 426
unintended consequences 431, 432, 433, 434–5, 437, 444, 448–9
choices about forms of participation
(participatory evaluation feature) 120, 122–4
CIA (conditional independence assumption) 40
citizen science projects 126
citizenship rights 203–5, 218–19
civil rights 204
Clark, R. 3
Clarke, J. 176–7, 210, 378
Clarke, Kenneth 265
Clayton, S. 214
CNIG (Cuban National Center for Scientific Research) 318
Coalition government (UK) 209, 213, 264, 266, 364, 366, 367–70, 375, 378
coarsened exact matching 43
Cochrane Centre 101, 468
Cochrane Collaboration 22, 24
coding data 132–3
cognitive capacity 331
Cohen, D.K. 144
Cohen, M. 147
collaborative relationships 421–2, 423, 426
collective bargaining 347
Comans, A. 338
commodification of individuals and social processes 271–2
common good 162, 263, 271
common support problem 44
‘comprehensive’ CBA 81, 86, 87–8, 95, 96
compute the net present value (CBA step) 78, 84–5
concentration curves 474, 488–90, 491
conceptual confusions 194
conditionality 162, 163, 166, 168, 170, 174, 175–6, 364–5, 366, 367–8, 369–70, 373, 375
confounders 41, 42–3, 45, 183, 285, 333–4, 518
consumer objects, research as 494–5
act of consumption 497–501
and Baudrillard 494, 496–8, 500, 501–3, 508–9, 512
and education 494, 497, 503, 507–9
functional research 509–12
luxury research 501–4, 505–6, 511
ornamental research 506–9
types of research 495–6
and value of consumer goods 496–503, 509–10, 511, 512
consumption, act of 497–501
content validity 332
continuous feedback 461, 465–6
continuums of control 122
control variables 20, 21, 30
Cooper, Z. 293
cooproduction of research 147
CORC (Child Outcomes Research Consortium) 403, 416–19, 425, 426
corporate bias 305–6, 312, 313–14, 316, 317
corporate social responsibility (CSR) 66, 67
‘cottage industries’ 324–5
covariates 40–41, 42, 43–5, 46–7, 48, 50
Cox, Eva 170
Coyle, S. 27
CPAG (Child Poverty Action Group) 371
CPP–D (Canada Pension Plan Disability Benefit) 216
CRD (Centre for Reviews and Dissemination) 101, 105, 107
‘creaming’ 235–6, 270, 375–7
Crépon, B. 355
‘critical participatory action research’ 121
Cronbach’s alpha 332
Crossing the Quality Chasm 282, 284
‘crowding out’ effects 360
crowdsourcing 121, 131
CRTs (cluster randomized trials) 16, 23, 27, 29–31, 32
CSD (Committee on the Safety of Drugs) 306–7
CSM (Committee on the Safety of Medicines) 307
CUA (cost-utility analysis) 73, 87, 90–91, 95, 96, 326, 333
‘cumulative advantage’ 433
CV (coefficient of variation) 474, 486
D’Addio, A.C. 350–51
Dahler-Larsen, P. 252
D Dalton Plan 22
DALYs (disability-adjusted life years) 184, 196
Daniel of Judah 21
Danish Clearinghouse for Educational Research 505
Darby, D. 511
Davies, B. 282
Davis, C. 312–13, 314
De Agostini, P. 483
de Cuyper, P. 394
Deacon, B. 365–6
deadweight 66, 70, 72
Dean, Hartley 162–3, 172
Dean, Malcolm 174
Dean, Mitchell 169, 170, 175
decide whose benefits and costs count
(CBA step) 78, 79–80
‘declaratory authority of science’ 125
DEFF (design effect) 31
definition of objectives (CBA step) 60, 61, 64
Dehue, T. 22
Del Boca, D. 445
Deleeck, Herman 432–3
demand pull model 420
Dementia Care Mapping 331
Dengue Torpedo 132
description of context (CBA step) 60, 61, 64
developing economies
and ‘development impact bonds’ 266
evaluation in 162–6, 167–8, 170–74
and evidence-based policy-making 196–7
and poverty 164–6, 167–8, 172, 173, 471, 472
and randomized controlled trials 163–4, 174
‘development impact bonds’ 266
DI (Disability Insurance) 217
difference-in-differences analysis 46–8, 353, 437, 439–40
direct effects 352–3, 356, 360
‘disability paradox’ 330
Disability Rights Movement 219, 371, 377
discount the benefits and costs (CBA step) 78, 84
disintegration 383
displacement 66, 70, 235, 355
disposable income 472, 473, 474, 475, 476, 478, 481–2, 484, 485, 487–90
dissemination 101, 105, 107, 113, 122–4, 128–9, 130, 418, 420–22, 423, 504, 505, 510, 512
‘diswelfares’ 204, 207, 219
DIY Health project 407–10
documentation (in performance management systems) 233–4
Dodd, S.C. 21
Dong, N. 31
Donner, A. 29
Donnison, D. 148
‘dose-effect relationship’ 294
drop-off 70
Drug Amendment (1962) 311
drug safety 303, 306–7, 310–12, 313, 314, 316–17, 318
Dryzek, John 176
DSP (Disability Support Pension) 216, 365
Dudley, P.M. 95
Duflo, Esther 164–5
Dustmann, C. 440
Dutch Knowledge Chamber 505
Duval, R. 347
DUWC (Derbyshire Unemployed Workers Centre) 374
DWP (Department of Work and Pensions) 212, 214, 368, 371, 372, 373, 374
early interventions 5, 153
EBM (evidence-based medicine) 300, 308, 319
EBPM (evidence-based policy-making)
141–3, 155–7, 242–4, 259–60
and active social policy 161–2
and best practice 250, 252, 255
and bias 248, 256, 259
case study 195–7
children, young people, and family
interventions 403, 405, 419–26
and complexity of social problems
256–7
definitions of 143–4
and developing economies 163, 168
and education 494, 503, 504–5, 507–12
and effectiveness of programmes
189–90
and ethics 246, 253
European initiatives 504–5
evidence narratives 170
evidence/decision-making gap 251–2
evidence/practice gap 249–51
evolution of 141
functional research 509–12
future of 141–2
‘ideal’ of 494
and knowledge 242, 243, 244, 249, 250, 251–2, 254–6, 258–9, 260
and labour markets 352
lack of relevance for practice 242–3, 247, 249–52, 259
limitation of 156
low evidence-bases 245
luxury research 501–4, 505–6, 511
and medicine 245, 246–7, 250, 255–6, 300, 308, 319
models of policy-making 144–8
and New Labour government 141, 142, 150–55
ornamental research 506–9
political factors 143–4, 145, 146
‘policy-ready’ evidence 494–5
poor application of policy 259–60
practical problems in producing
evidence 242, 244–51, 259
in practice 150–55
and professional autonomy 254–5
and randomized controlled trials
153, 154, 155, 244, 246–8, 255–6, 258
and ‘research impact’ 143, 156–7, 421
and social impact bonds 263
sociological and ideological factors
243–4, 252–9
and Sure Start programme 151, 152–4, 155, 156
and technocratization of values
252–4
theories about policy change 148–50
‘use’ and ‘misuse’ of ‘evidence’ 242, 244–5, 252
washback effects on scientific
practice 258–9
and ‘what works’ 252–4
and Work Capability Assessments
366, 378
EBPU (Evidence Based Practice Unit)
403, 405, 425
EC (European Commission) 438
ECEC (early childhood education and
care) services 432
economic (CBA evaluation dimension)
60
economic analysis (CBA step) 61, 62–3, 64–5
Economic and Social Research Council
366
economic evaluation of policies
alternative methods 86–91
cost–benefit analysis 77–86, 87–8, 92–6
cost-effectiveness analysis 77, 87, 88–90, 91, 95, 96
cost-utility analysis 87, 90–91, 95, 96
and equity 92–3
multi-sectoral CBA 94–5
economy (performance criterion) 228, 229
Edison, Thomas 495–6
education
and cost-effectiveness analysis 88, 183–4
and evidence-based policy-making
494, 503, 504–5, 507–12
and integration policy evaluation
389, 390, 393, 397, 399, 400
and randomized controlled trials 17–20, 22, 23, 24, 29–31, 34
and research as a consumer object 494, 497, 503, 507–9
Education Act (1944) 203
Education Endowment Foundation 196, 504
effective (healthcare evaluation metric) 284
effectiveness (performance criterion) 228, 229–30
efficiency (performance criterion) 228, 229
efficient (healthcare evaluation metric) 284
EIPEE (Evidence Informed Policy in Education in Europe) 504–5
Eisenstadt, N. 153
elixir sulphanilamide 311
EMA (European Medicines Agency) 308
embedded model 421
Emerson, J. 67
Emotion Maps 131
employment/unemployment
active labour-market policies 351–60
and developing economy evaluations 172–3
employment protection regulation 345, 346, 347–9, 350, 351, 354, 360
and family policies 434, 436–7, 438–40, 441, 444–6, 448–9, 450
and integration policy evaluation 384, 385, 387, 388–90, 393, 394–6, 397, 399–400
labour market institutions and reforms 345–51
and minimum wage policies 485–7, 488, 491
and poverty 476–7, 485–7, 488, 491
and quasi-experiments 48
and results-based financing 197–8
and Work Capability Assessments see WCAs
see also labour market
Empowering People to Work 368
Encyclopedia of Corporate Social Responsibility 67
ends-based rationales 124, 125–6, 128–9
English Indices of Deprivation 210
enlightenment model 145, 147–8, 421
Enlightenment period 144
environmental (CBA evaluation dimension) 60
EPPE (Effective Provision of Preschool Education) project 445
EPPI (Evidence for Policy and Practice Information and Co-ordinating Centre) 101, 114, 503–4
‘equal trends assumption’ 47
equitable (healthcare evaluation metric) 284
equity and fairness (performance criterion) 228, 230
ERSA (Employment Related Services Association) 376, 379
ESA (Employment and Support Allowance) 211, 212, 213–14, 216, 218, 364, 367, 368, 369, 370–71, 373, 374–5, 377
ESRC (Economic and Social Research Council) 151
establishing impact (SROI stage) 68, 70, 72
establishing scope and identifying stakeholders (SROI stage) 68–9, 71
ethics
and evidence-based policy-making 246, 253
and human rights 174–5
and medicine 517
and participatory evaluation 120, 133–5
and poverty 38
and randomized controlled trials 33, 38, 174, 246
EU (European Union)
and evidence-based policy-making 141
integration policy evaluation 386, 392–3
and medicines evaluation 308
and performance measures 231
and poverty measurement 473, 476, 490
EUROMOD (tax–benefit model) 476
Handbook of social policy evaluation

European Community Household Panel study 350–51
European Labour Force Survey 351
European Social Survey 391
EUROSTAT 351
EU-LFS (European Labour Force Survey) 441
EU-SILC (European Union Statistics on Income and Living Conditions) 446–7, 476, 490
evaluation utility 187
evaluation, defining 3–6, 225, 516
Evans, I. 22
evidence evaluations and narratives 169–74
evidence hierarchy 6, 102–3, 105, 108, 116, 154, 163–4, 244, 319
evidencing outcomes and giving them a value (SROI stage) 68, 69–70, 71–2
EVIPNet (Evidence-Informed Policy Network) 142
exchange value of consumer goods 497, 500, 501, 512
expected net benefits 92–3
‘expert evidence’ 251
external validity 32, 39, 53, 285, 333, 397

fairness 92–3, 228, 230, 246, 271, 302
Family Allowance Act (1945) 203
family policies see children, young people, and family interventions
Family Resources Survey 484
FDA (Food and Drug Administration) 310–14
FDTCs (family drug treatment courts) 45
feedback intervention theory 416
Fernandez, J.-L. 210
Ferrans, C.E. 334, 335, 336
fertility rates 431, 437, 438, 441
FGT (Foster-Greer-Thorbecke) poverty measure 473, 484, 486, 490
‘fictitious’ commodities 271
Field, Frank 211
financial analysis (CBA step) 60, 62, 64
financial discount rate 62, 64
Finckenauser, J.O. 21
Finn, J. 23
Fisher, Ronald 21
fixed-term contracts 346, 348–51
Flay, B.R. 34
Fleming, I. 419
‘flexi jobs’ 217
Flexible New Deal 264, 272
focus groups 26, 335, 405, 409, 410, 411, 414
Food and Drug Administration Modernization Act (FDAMA, 1997) 311, 312
Food, Drug and Cosmetic Act (1938) 311
Food and Drugs Act (1947) 314
Forsetlund, L. 22
foster care 39
Foster, J. 473
Fothergill, S. 209, 212
Freedom of Information Act (1967) 314
freedom of speech 204
functional research 509–12

Gabe, J. 316, 317
Gaebler, T. 206
‘generative’ approach 104
‘garbage can’ model 147
Garibay, M.G. 394
Garthwaite, K. 213, 214, 215
Gash, V. 350
Gassmann, F. 436
Gauthier, A.H. 437
gender equality 205–6, 431, 432, 438, 440, 444
generality, levels of 110
Gertler, P.J. 49–51
Gini coefficient 230
Glass, G.V. 100
Glass, Norman 152
GlaxoWellcome 310
global financial crisis/Great Recession 209, 296–4, 345, 351, 352
globalization 205, 207, 495
goal displacement 235
‘gold standard’ 6, 22, 82, 154, 163, 174, 285, 319
Index 529

‘golden age’ of welfare 204
‘golden triangle’ of science 125, 136
González, L. 437
Goodson, L. 122
Gornick, J.C. 490
Gough, D. 105, 504–5
GP (General Practice) attendance 407–10
Green Book (HM Treasury) 121
Green, S.L. 45
Grek, S. 508
Grewal, I. 329
‘group randomized trials’ 16
Grover, C. 219
Gueron, J. 27, 33
guiding principles rather than specific method (participatory evaluation feature) 120, 127–31
Gutiérrez Romero, R. 48
‘hackathons’ 132
Hagen, T. 349–50
Hahn, R.W. 95
Hainmueller, J. 358
Hall, Peter 170
Hammersley, M. 102, 103
happiness 2, 5
‘hard to reach/research/hear’ topics 126
‘hard’ incentives 234
Hardoy, J. 439
Hargreaves, A. 511
Hargreaves, D. 509
Harrington, Malcolm 215
Harris, A. 511
Havnes, T. 446
‘Hawthorne effect’ 171
Hayek, F. 205
Hayes, R. 27, 29
HCA (home-care allowance) 448–9
Head Start Program 22, 152–3, 156, 445
health insurance 279, 288–90, 310
healthcare systems
asylums 295–6
choice and competition 291–3
complexity of 286
cost and outcome considerations 286–7
and cost-effectiveness analysis 88, 91, 184
DIY Health project 407–10
evaluation examples 287–96, 297
evaluation frameworks 282–4, 297
and evidence-based policy-making 146, 196–7
financing healthcare 287–90
and health insurance 279, 288–90
and health needs 279–80, 296–7
and health policy 280–81
need for evaluation 279–81
observational studies 285
pay-for-performance initiatives 290–91
performance of 282, 284, 290–91
and prepayment systems 287–8
production of welfare framework 282, 283
and randomized controlled trials 285, 289–90, 293, 297
state of the art evaluation 285–7
tackling stigma 293–5
see also medicine
health visitors 407, 408, 411–14
Heberprot-P 318
Heckman, J. 5
Hellström, Y. 337
Henderson, M. 144
Herceptin 316–17
hierarchical linear modelling 29–30
hierarchy of evidence 6, 102–3, 105, 108, 116, 154, 163–4, 242, 244, 319
Hill, Austin Bradford 22
Hillage, L. 511
‘historical institutionalism’ 149
HLM software 30
horizontal equity 230
HRQoL (health-related quality of life) measurement 325, 326, 327, 329, 337, 339
Huddleston, T. 388, 390, 391
human rights 27, 162, 169, 171, 173, 174–5, 295
Hume, David 144
Hussain, M.A. 490
hyperreality 508–9
IADLs (instrumental activities of daily living) 324
IB (Incapacity Benefit) 211, 212, 214, 368, 369

ICC (intra-class correlation) 31, 32
ICECAP-O (QoL instrument) 328, 334, 335, 336, 337, 338
ICER (incremental cost-effectiveness ratio) 89, 309
ICH (International Conference on Harmonisation) 305
ICPSR (Inter-university Consortium for Political and Social Research) 34
identification of project (CBA step) 60, 61, 64
identify impact categories (CBA step) 78, 80–81
‘ideological evidence’ 251
IES (Institute of Education Sciences) 22, 34
‘illiberalism’ 175
Imai, K. 29
Imbens, G. 33
immigrants, integration of see integration
impact effects 187, 193, 196
impact evaluation tools 192
impact maps 66, 69, 71
impact matrix 81, 93
IMPACT recommendations 426
impact theory 233
‘inclusiveness and monetization of benefits’ 86, 87
‘inclusiveness and monetization of costs’ 86, 87
‘incomplete’ CBA 81, 86, 87–8, 96
indirect effects 355, 360
informal care 324, 325, 326–7, 329, 337, 338–9
informed consent 134
INGA (in-house intensified service delivery) 360
innovation, downgrading of 235
input–output–outcome models 228
Institute for Fiscal Studies 476
Institute of Medicine 282, 284
‘institutionalized individualism’ 257
instrumental rationales 124, 125–6
instrumental variables 43
integration policy 383–4, 399–400
and active citizenship 389, 391, 399
cross-national comparisons 394
dimensions of integration 387–92, 400
and education 389, 390, 393, 397, 399, 400
entity of integration 393, 396–7
and equality 384, 385
evaluation approaches 393–9
focus of evaluation 385–7
general outcome evaluation 386
implementation studies 396–8
labour market integration 384, 385, 387, 388–90, 393, 394–6, 397, 399–400
participant perspective 398–9
policy evaluation 385–6
policy outcome evaluation 386–7
and social cohesion 383, 387, 388
and social inclusion 387, 389, 390–91, 399–400
target groups 392–3
two-way process of integration 383, 384, 391, 399
and welcoming society 389, 391–2
Zaragoza indicators 386, 387–8, 389, 390–91
interaction model 420–21
interactive model (of science/policy relationship) 145, 147
interactive public consultation 132
intercepts-and-slopes-as-outcomes models 30
‘interest’ issues 519
internal validity 16–17, 38, 42, 49, 52–3, 103, 105, 109, 285, 332
International City Managers’ Association 223
International Financial Reporting Standards 66
‘interplay’ of research 148
intervention (programme theory) 404, 406, 408, 413, 415
intervention theory 233
IPA (Innovations for Poverty Action) 192
Iressa 313–14
Jacobs, K. 379
Jäntti, M. 490
JCAs (Job Capacity Assessments) 216,
<table>
<thead>
<tr>
<th>Index 531</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jenkins-Smith, H.C. 149, 152</td>
</tr>
<tr>
<td>Jobcentre Plus 369, 370–71, 373, 376</td>
</tr>
<tr>
<td>Jobs Strategy (OECD) 346, 347</td>
</tr>
<tr>
<td>Jones, B. 149</td>
</tr>
<tr>
<td>Joona, P.A. 395</td>
</tr>
<tr>
<td><em>Journal of Experimental Criminology</em> 24</td>
</tr>
<tr>
<td><em>Journal of Research on Educational Effectiveness, Trials, Clinical Trials</em> 24</td>
</tr>
<tr>
<td><em>Journal of the American Statistical Association</em> 24</td>
</tr>
<tr>
<td><em>Journal of the Royal Statistical Society</em> 24</td>
</tr>
<tr>
<td>journals 304, 418</td>
</tr>
<tr>
<td>J-PAL (Abdoul Latif Jameel Poverty Action Laboratory) 24</td>
</tr>
<tr>
<td>JSA (Job Seeker’s Allowance) 211, 214, 369, 371, 375, 376, 377</td>
</tr>
<tr>
<td>Jurin, James 21</td>
</tr>
<tr>
<td>JustFair 377</td>
</tr>
<tr>
<td>Kane, R.A. 329</td>
</tr>
<tr>
<td>Kao Zheng 21</td>
</tr>
<tr>
<td>Kappa statistics 108</td>
</tr>
<tr>
<td>Kasza, G. 207</td>
</tr>
<tr>
<td>Kefauver, Carey 311</td>
</tr>
<tr>
<td>Kelsey, Frances 311</td>
</tr>
<tr>
<td>Kendall, G. 206, 207</td>
</tr>
<tr>
<td>Keynesianism 205, 219</td>
</tr>
<tr>
<td>King, Desmond 175</td>
</tr>
<tr>
<td>King, R. 206, 207, 392, 393, 396</td>
</tr>
<tr>
<td>Kingdon, J.W. 149</td>
</tr>
<tr>
<td>Kinsey Institute 126</td>
</tr>
<tr>
<td>Kitson, A. 103, 104</td>
</tr>
<tr>
<td>Klar, N. 29</td>
</tr>
<tr>
<td>Kluve, J. 441</td>
</tr>
<tr>
<td>Knapp, M. 282</td>
</tr>
<tr>
<td>knock-on effects 82</td>
</tr>
<tr>
<td>knowledge (in evidence-based policymaking) 242, 243, 244, 249, 250, 251–2, 254–6, 258–9, 260</td>
</tr>
<tr>
<td>knowledge brokers 147</td>
</tr>
<tr>
<td>knowledge transfer 151</td>
</tr>
<tr>
<td>knowledge translation 142</td>
</tr>
<tr>
<td>knowledge-driven model (of science/policy relationship) 145–6</td>
</tr>
<tr>
<td>'knowledge-to-action gaps' 146–7</td>
</tr>
<tr>
<td>Koebel, K. 437–8</td>
</tr>
<tr>
<td>Konstantopoulos, S. 23</td>
</tr>
<tr>
<td>Kopeinig, S. 42</td>
</tr>
<tr>
<td>KPIs (key performance indicators) 224–5, 232, 238</td>
</tr>
<tr>
<td>KS (Kommunernes Sentralforbund) 459</td>
</tr>
<tr>
<td>Kuksov, D. 499</td>
</tr>
<tr>
<td>labour market</td>
</tr>
<tr>
<td>active labour-market policies see ALMPs 345, 346, 347–9, 350, 351, 354, 360</td>
</tr>
<tr>
<td>and fixed-term contracts 346, 348–51</td>
</tr>
<tr>
<td>institutions and reforms 345–51, 354, 360</td>
</tr>
<tr>
<td>and integration policy evaluation 384, 385, 387, 388–90, 393, 394–6, 397, 399–400</td>
</tr>
<tr>
<td>and job creation 345, 346, 348</td>
</tr>
<tr>
<td>and Welfare State 206, 207, 212–13, 214, 216, 217, 218–19</td>
</tr>
<tr>
<td>see also employment/unemployment 211, 214, 369, 371, 375, 376, 377</td>
</tr>
<tr>
<td>Landier, A. 349</td>
</tr>
<tr>
<td>Lappegård, T. 440–41</td>
</tr>
<tr>
<td>'lay evidence' 251</td>
</tr>
<tr>
<td>lay expertise/knowledge 122, 123, 124, 125–6, 128, 130, 134–5</td>
</tr>
<tr>
<td>Layard, R. 346</td>
</tr>
<tr>
<td>Le Grand, Julian 450</td>
</tr>
<tr>
<td>'league tables' 90</td>
</tr>
<tr>
<td><em>learning</em> (in performance management systems) 233, 234</td>
</tr>
<tr>
<td>Lechner, M. 396</td>
</tr>
<tr>
<td>Lefebvre, P. 446</td>
</tr>
<tr>
<td>Lemieux, T. 52</td>
</tr>
<tr>
<td>Levin, H.M. 27</td>
</tr>
<tr>
<td>Levitas, Ruth 378</td>
</tr>
<tr>
<td>LGR (Local Government Reform) 457</td>
</tr>
<tr>
<td>Liao Shicheng 21–2</td>
</tr>
<tr>
<td>libertarian paternalism 162</td>
</tr>
<tr>
<td>'life of policies' 78, 81, 84</td>
</tr>
<tr>
<td>Light, D.W. 311, 316</td>
</tr>
<tr>
<td>Liket, K.C. 185, 194</td>
</tr>
<tr>
<td>Limited Capability for Work Questionnaire 370</td>
</tr>
<tr>
<td>Lindblom, C.E. 144</td>
</tr>
<tr>
<td>Lindquist, E.A. 147</td>
</tr>
<tr>
<td>Lipsky, M. 397</td>
</tr>
</tbody>
</table>
Marshall, T. 204, 205
Martin, R. 207
Martineau, P. 506–7
Masterov, D. 5
Mathematica Policy Research 25
Matsaganis, M. 436
‘Matthew effect’ 433, 436, 441, 449
Mauss, Marcel 465
Maximus Healthcare 212, 214, 377
Maynard, R.A. 31
MBO (management by objectives) 223
MBOR (management by objectives and results) 223
MCA (Medicines Control Agency) 307
MCA (multicriteria analysis) 59, 73
MDGs (Millennium Development Goals) 163
Mead, Lawrence 168
means-tested benefits 436, 381–2
‘media evidence’ 251
Medicaid 289

medicine
and ethics 517
and evidence-based policy-making 245, 246–7, 250, 255–6, 300, 308, 319
evaluation of 300–301, 318–19
accelerated approval processes 312–13
case studies 306–17
and corporate bias 305–6, 312, 313–14, 316, 317
in Cuba 317–18
drug safety 303, 306–7, 310–12, 313, 314, 316–17, 318
industry-funded research 304
in New Zealand 314–17
positioning of the pharmaceutical industry 303–6
purposes and processes of drug regulation 301–2
and randomized controlled trials 22, 302
sociological context 302–6
in UK 306–10
in US 310–14
see also healthcare systems
MEDSAFE (Medicines and Medicinal
Index 533

Devices Safety Authority 314, 316
Mercy 253
Merton, Robert 433
‘messy’ studies 116
meta-analysis 15, 24, 100, 101, 103, 106, 111, 113, 115, 196, 353–4, 388
methodological pluralism 195
MHRA (Medicines and Healthcare products Regulatory Authority) 307
Mi Familia Progresa programmes 166
micro-processes of utilization 419–20
Middlesex University 366
MIKMOD-Est (tax–benefit model) 476
Milligan, K. 52, 437, 440
MINDFUL approach 418, 426
minimum wage policies 485–7, 488, 491
Mintzberg, Henry 232
MIPEX (Migrant Integration Policy Index) 385
MIT (Massachusetts Institute of Technology) 24
moderators (programme theory) 404, 406, 408, 413
‘Modernising Government’ agenda 150, 403, 425
‘modified’ CEA 90
Mogstad, M. 446
monetize all impacts (CBA step) 78, 83–4
Moneyball for Government 196
Monte Carlo analysis 78, 85, 95, 96
moral hazard 264, 271, 288
Morgan, K. 29
Morris, J. 378
Mosteller, F. 27
Motivation (in performance management systems) 234
Moulton, L. 27, 29
Mouter, N. 95
MTAs (multiple technological appraisals) 309
Mulgan, Geoff 143
Müller, K.-U. 485
multiculturalism 383
multi-level analysis/modelling 53, 115
multi-sectoral CBA 94–5
Murray, D.M. 27
‘myopic’ individuals 83
NAO (National Audit Office) 171
National Bureau of Economic Research 25
National Health Service Act (1946) 203
National Institute for Public Health and the Environment 142
National Insurance Act (1946) 203
‘natural experiments’ 16
naturalization 389, 391, 392
NAV (Norwegian Labour Market and Welfare Administration) reform 456, 457, 459–61, 463, 466–9
NDC (New Deal for Communities) program 48
NEETs (not in education, employment or training) 390
NEF (New Economics Foundation) 67
Nekby, L. 395
neoliberalism 203, 204, 205–7, 210–11, 220, 312, 318, 366, 378
New institutional economics 206
New Labour government (UK) 141, 142, 150–55, 211, 213, 264–5, 308, 364, 365–6, 367–9, 375, 503
Newman, J. 207, 210, 378
Newstart Allowance 216, 365
Neyman, Jerzy 21
NGOs (non-governmental organizations) 185, 192, 196–7, 377
NICE (National Institute for Health and Care Excellence) 308–10, 315, 316, 334, 411
Nickell, S. 346
Nieuwenhuis, R. 437, 441
Noble, M. 48
non-equivalent comparison groups 39, 41–2, 44, 45, 48, 49, 50, 53
non-linear regression techniques 52
non-profit organizations 63–4, 67–8, 71, 185, 189–91, 192
normative rationales 124–5, 126
normative theory 233
Norwegian Integration Barometer 392

Bent Greve - 9781785363245
Downloaded from https://www.elgaronline.com/ at 11/01/2023 08:29:22AM
via free access
outcome effects 187
outcomes (programme theory) 404, 406, 408, 413, 415
out-of-market prices 65
out-of-pocket payments 287, 288, 290
Overseas Development Agency 143
P4P (pay-for-performance) initiatives 290–91
parental leave schemes 431, 432, 433, 438–44, 446–7, 449
‘parking’ 270, 375–7
Participatory Chinatown 132
participatory evaluation 119–20
active involvement of groups 120–22
belief in benefits of participation 120, 124–6, 127, 128–30
choices about forms of participation 120, 122–4
common and distinctive features 120–31
crowdsourcing 121, 131
and dissemination 122–4, 128–9, 130
ends-based rationales 124, 125–6, 128–9
ethical and methodological issues 120, 133–5
guiding principles rather than specific method 120, 127–31
and lay knowledge 122, 123, 124, 125–6, 128, 130, 134–5
levels of challenge and skill 122–4, 127–31
participatory data collection 131–3
practical tools and techniques for participation 131–3
and quality of research 135–6
and randomized controlled trials 127
stages of policy evaluation research 122, 123, 127–30
value-based rationales 124–5, 126, 128
passive labour market policies 351
passive use benefits 80
passive use impacts 80
Pasteur, Louis 495–6
‘Pathways to Work’ programme 212, 213, 368
patient-centred (healthcare evaluation metric) 284
Patton, M.Q. 187, 465
Pawson, R. 102, 103, 104, 116, 143
payback period 70, 71
PbR (payment by results) initiatives 185, 264, 265, 267, 268, 269, 270, 272
PBs (Personal Budgets) 293, 328, 337–8
PCA (Personal Capability Assessment) 373
Pearce, J. 207, 210
Pearl, J. 43
peer champions 423
peer-review journals 304, 418
Peirce, Charles Sanders 21
perform sensitivity analysis (CBA step) 78, 85
Performance Beyond Expectations 511
performance criteria 227–31
performance culture (in performance management systems) 234
‘performance’/‘effectiveness’ distinction 190–92, 199
perinatal mental health value Scorecard 410–15
PES (public employment service) 356, 357, 358, 359, 360
Peterborough Prison 265–6, 267, 269, 272
Petrosino, A. 21
Petticrew, M. 104, 108
PHARMAC (Pharmaceutical Management Agency) 314–17
PHBs (Personal Health Budgets) 293
Phillimore, J. 122
photography 133
PIAAC (Programme for the International Assessment of Adult Competencies) 390
PICOS (Population, Intervention, Comparator, Outcomes, and Study) process 105–6, 107
Pielke, R. 507
Piggott, L. 219
PISA (Programme for International Student Assessment) 390, 507–8
‘place randomized trials’ 16
‘placebo’ candidates 198
Plantenga, J. 439, 445–6
PM (performance management) 223–4, 236, 238
defining 223, 224–5, 236
and evaluation 225–7, 236, 238
increasing use of 223, 236
and key performance indicators 224–5, 232, 238
and knowledge 250
and new public management 223, 227, 229
and performance targets 224, 225, 238
PM systems 233–6, 237, 238
processes of 224–6, 238
public sector decision-making processes 233–6
public sector performance criteria 227–31
public sector performance measurement 231–2
and use of performance data 225–6, 233–6, 238
‘points of reference’ 227–8
Polanyi, Karl 271
policy agora 505–6
‘policy entrepreneurs’ 149
policy streams 149
policy transfer 142
‘policy-ready’ evidence 494–5, 501
political model (of science/policy relationship) 145, 146
political rights 204
Pollock, M.D. 45
‘polycentric’ regulation regimes 302–3
poor data collection 195, 199
Popper, K. 111
Porter, S. 209
postnatal depression 410–15
post-test-only comparison group design 41–5
potential outcome model 39–40
poverty
behavioural approach to social policy analysis 476–7, 486–7, 490
cross-national social policy comparisons 477–83, 491
Danish social benefits 487–90, 491
and developing economies 164–6, 167–8, 172, 173, 471, 472
disposable income measures 472, 473, 474, 475, 476, 478, 481–2, 484, 485, 487–90
distributional effects of social policy 471, 475–8, 487
and employment 476–7, 485–7, 488, 491
and ethics 38
German minimum wage policy 485–7, 488, 491
intervention goals 471
and labour supply effects 476–7
means-tested benefits 481–2
measurement of 471–4, 490
non-means-tested benefits 481–2
poverty indicators 473–4
poverty lines 471, 472–3, 478, 481–2, 484–8, 490–91
and quasi-experiments 49–51
sensitivity to social policy changes 474–7
specific national policy evaluations 483–90
static approach to social policy analysis 475–6, 486, 490
and tax–benefit systems 475–6, 477–83, 484, 485, 491
UK child benefit package 483–5, 491
Powers, M.J. 334, 335, 336
PPRS (Pharmaceutical Price Regulation Scheme) 307–8
practolol 307, 312
Pratchett, L. 209
predict impacts quantitatively (CBA step) 78, 81–2, 94
preference-based instruments 333, 334
prepayment systems 287–8
Prescription Drug User Fee Act (PDUFA, 1992) 311, 312
pre-test-post-test comparison group design 45–8, 49
pre-treatment heterogeneity bias 42
preventative initiatives 3
principal–agent dilemma 4
problem-solving model (of science/policy relationship) 145–6
process indicators 325–6
production of welfare framework 282, 283
professional autonomy 254–5
programme theories 4, 5, 404–6, 407–9, 413, 415, 426
PROMs (patient-reported outcome measures) 328
Prospera (Oportunidades/Progresa) trials 23, 165, 170
proxies 331, 338
PSM (propensity score matching) 43–5, 48, 353, 418
PTAC (Pharmacology and Therapeutics Advisory Committee) 315
public-sector reforms 456–7, 468–9
actors in large-scale reforms 462–3
attention points 456, 457, 459, 460–69
characteristics of large-scale reforms 457–8
continuous feedback 461, 465–6
data generation and analysis methods 459–60
dilemmas 456, 457, 459, 460
evaluating impact 467–8
evaluation objectives 460–61, 462, 465–6
external research-based evaluation 460–62
flexibility in evaluation process 466–7
integrating research modules 467
meta-evaluation of 456–7, 459–60, 461, 462, 466–9
paradoxes 456, 457, 459, 466
previous evaluative research 457–9
steering committees 459, 462, 463–4, 467
and trade-offs 456, 457, 459, 460, 462, 464, 469
punctuated equilibrium theory 149
Purdue University 22
pure applied research 495–6
pure basic research 495–6
PV (present value) 78, 84–5, 88, 92, 94
QALYs (quality-adjusted life years) 90–91, 308, 309, 316, 317, 326, 327
QI (quality improvement) tools 411, 413–14
QLI (Quality of Life Index) 334, 335, 336
Index 537

QoL (quality of life) measurement 323–4, 325, 326–7, 331–4, 337–9
defining QoL 327–31
instrument examples 334–6
quality (performance criterion) 228
quality appraisal 73–4, 101, 108–10, 114–16, 117
Quality of Government Institute (Gothenburg University) 231
quasi-experiments 38–9, 52–4
and active labour-market policies 358
and bias 40–41, 42–3, 44–5, 46, 47, 48, 52–3, 189
and counterfactuals 39–42, 44, 45, 47–8, 51
and external validity 39, 53
and higher-order units 53
and impact evaluation 189
and internal validity 38, 42, 49, 52–3
and non-equivalent comparison groups 39, 41–2, 44, 45, 48, 49, 50, 53
post-test-only comparison group design 41–5
pre-test-post-test comparison group design 45–8, 49
and randomized controlled trials 16–17, 20, 21, 38, 42, 45, 53
and regression discontinuity design 49–52
question formulation 192–4, 199
‘quick-and-dirty’ analysis 464
RAND Corporation 25, 289
Randomized Social Experiments eJournal 24
Ratcliffe, J. 337
‘rational analysis’ 143
Raudenbush, S.W. 27, 29
RCTs (randomized controlled trials) 6, 15
access to data 33–4
and active labour-market policies 355, 359
assuring balance 28–9
and bias 15, 16, 18–19, 20, 23, 248, 285
children, young people, and family interventions 415, 426
cluster randomized trials 16, 23, 27, 29–31, 32
contemporary illustrations 22–3
texts of 25–7
control variables 20, 21, 30
and cost–benefit analysis 82
cost-effectiveness analysis 26–7
definitions 15–16
disagreements and contentions 31–3
empirical portrayal 20–21
estimating effectiveness 26
and ethics 33, 38, 174, 246
and evaluation of medicine 302
and evidence-based policy-making 153, 154, 155, 244, 246–8, 255–6, 258
graphical portrayal 17–19
and healthcare system evaluation 285, 289–90, 293, 297
hierarchical and complex trials 29–31
historical development of 21–2, 27–8
in developing economies 163–4, 174
intervention process 26
journals 24
methodologies 26, 195
organizations 24–5
and participatory evaluation 127
and public-sector reforms 468
and quality assurance 248
and quasi-experiments 16–17, 20, 21, 38, 42, 45, 53
rationale 16–17
realities of 33
simple trials 28
social context 27
and social impact bonds 197
statistical model portrayal 19–21
trial design and results analysis 27–31
vernacular 16
RDD (regression discontinuity design) 49–52
realist synthesis 100, 103–4
realistic evaluation 249, 404–10, 414, 415, 425–6
REDF (Roberts Enterprise Development Fund) 67
Reed, T. 305
REF (Research Excellence Framework) 156
Reform Act (1832) 204
‘regime’ effects 357
regional cumulative differential growth 207, 208
regressor variable method 48
‘regular municipality treatment’ 198
regulatory capture theory 305–6
Rein, M. 148
relative evaluation 60
Refenza 309–10
reliability (of QoL instruments) 332
replication 15, 32, 33–4, 79, 102, 104, 487
reporting, using, and embedding (SROI stage) 68, 71, 72–3
Research Council of Norway 459, 460, 464
‘research impact’ 143, 156–7, 421
response burden 331–2
responsiveness (performance criterion) 228, 230–31
results-based financing 197–8
revealed preferences 63, 65, 472
Reynolds, S. 102
RFC (Residual Functional Capacity) assessments 217
Rhodes, R. 206
Ricucci, N.M. 226
Riecken and Boruch, H.W. 16
rigor, methodological 194–5
Rikers Island prison 266
Rinne, U. 388
risk assessment (CBA step) 61, 63, 65
Roberts, H. 104, 108
Roche 316–17
ROI (return on investment) 65–6, 74
Rolston, H. 27, 33
Rosenbaum, P. 32, 44–5
Rosholm, M. 350–51
routine outcome monitoring 415–16, 417–19, 425, 426
Royal Dutch DSM 188
Rubin, D. 29
Ruhm, C.J. 440
Rui, N. 24
Russo, P. 90
Sabatier, P.A. 149, 152
safe (healthcare evaluation metric) 284
Salanauskaite, L. 436
Sandel, M. 271
Sandelowski, M. 111, 113
Sanderson, I. 144, 156
SAS statistical software 30
Sat Lav 132
‘Scared Straight’ programs 20–21
Scherer, S. 350
Schirle, T. 437–8
Schmitz, S. 441
Schönberg, U. 439, 440
Schone, P. 439
Schutes, I. 375–6
Science 433
science push model 420
Scriven, Michael 225
SDR (Social Discount Rate) 62, 65, 78, 84
secondary effects 82
selection bias 18, 41, 45, 46, 52, 116, 189, 285, 518
self-employment 253, 388–90
self-regulation theory 416
self-treatment 279
Sen, Amartya 74, 327–8
sensitivity (of QoL instruments) 332
sensitivity analyses 44–5, 63, 65, 70, 72, 78, 85, 89
serendipity 147, 149, 511
Shadish, W. 38–9, 41, 52–3
shadow effects 258
Shaw, I. 259
SIBs (social impact bonds) 185, 263, 272–3
and austerity measures 263–4, 272
and commodification of individuals and social processes 271–2
and global financial crisis 263–4
manipulation of service provision 270–71
measurement and attribution of outcomes 268–70
moral considerations 263, 264, 270–72, 273
and payment by results initiatives
Index 539

185, 264, 265, 267, 268, 269, 270, 272
and performance measurement 270
in practice 265–7
and randomized controlled trials 197
rapid rise of 263–4, 266, 272–3
and results-based financing 197–8
risks of 267–70
and ‘social investment’ 264, 266, 267
in theory 264–5
‘sign’ value of consumer goods 497–8, 499
‘signifying’ value of consumer goods 500–502, 503, 509–10, 511
situation theory 233
Skinner, B.F. 161–2, 177
‘slow-and-clean’ analysis 464
SLP (Supported Living Payment) 216
Small, N. 399
Smith, Davey 141
Smith, M.L. 100
social (CBA evaluation dimension) 60
social accounting 57–8, 65
Social Care Institute for Excellence 107
social cohesion 271, 383, 387, 388
Social E-valuator 67
Social Finance 267, 269
social impact value chain 185–7, 191
social inclusion 387, 389, 390–91, 399–400
social investment 4, 5, 172, 175, 264, 266, 267, 432
‘social learning’ 170
social opportunity cost of capital 84
social rights 204–5, 207, 210, 219
social theory 148
social value 57, 59, 65–6, 67, 74, 75, 77, 184, 186–7, 191, 309, 319
social work/social workers 3, 217, 243, 246, 247–8, 250, 253, 255
SOEP (German Socio-Economic Panel) 485–6
‘soft’ impacts 80
‘soft’ incentives 234
Solesbury, W. 155
specify policy alternatives (CBA step) 78–9, 94
Spencer, L. 108
SPFs (social protection floors) 173
squared poverty gap 166, 168
SROI (social return on investment) 57, 65–7
and cost–benefit analysis 57–9, 65, 72, 73–5
further directions for quality appraisal 73–4
generalizations 58, 74
history of 67–8, 74
main principles 66–7
and sensitivity analysis 70, 72
simplified example of 71–3
and social accounting 57–8, 65
and social value 57, 59, 65–6, 67, 74, 75
and stakeholder decisions 58
and stewardship 58
technical stages for analysis 68–71, 75
SSI (Supplemental Security Income) 217
SSLPs (Sure Start Local Programmes) 153–4
Stabile, M. 437
Standing, Guy 176
‘standing’ 79–80, 81
Stanley, J. 16–17
Staples, L.H. 399
STAR (Tennessee class size trial) 23, 34
STAs (single technological appraisals) 309
stated preferences 63, 65
Statistical Sciences 24
‘statistical twins’ 353
Statistics Denmark 487–8
Statistics Norway 395
steering committees 459, 462, 463–4, 467
Steiner, V. 485
stigma 293–5
Stinchcombe, A.L. 110
Stokes, D. 495
storytelling 133
‘street evidence’ 251
‘street science’ 121
structure indicators 325–6
STSM model (Steuer-Transfer-Simulations-Model) 485
Stubbs, Paul 174
subjective well-being approach 63
Sun, M. 23
Handbook of social policy evaluation

Sundberg, T. 113, 114, 115, 117
Sure Start programme 151, 152–4, 155, 156
Sutherland, H. 483
Sutton, M. 291
'symbolic' value of consumer goods 497–9
systematic reviews 100–101, 117
and bias 101–2, 105, 107, 108, 116
and cost-effectiveness analysis 184
data extraction 110–11
data synthesis and analysis 111–13
and dissemination 101, 105, 107, 113
emergence and development of 100, 101–2
and hierarchy of evidence 102, 103, 105, 108, 116
inclusion criteria 105–6
main criticisms 102–4
and meta-analysis 100, 101, 103, 106, 111, 113, 115
practical issues 114
and quality appraisal 101, 108–10, 114–16, 117
and randomized controlled trials 163–4
and realist synthesis 100, 103–4
review process introduction 104–5
review process protocol 105–13
sample sizes 109, 112, 116
screening process 107–8
search strategy 107
study selection 107–10
and 'what works' tradition 100, 101, 103–4
tactical model (of science/policy relationship) 145, 146
Taylor, R. 375–6
Taylor-Goooby, P. 114, 176, 205–6
Teacher Training Agency 509
technical feasibility and environmental sustainability (CBA step) 60, 61–2, 64
technical issues of social policy evaluations 517–18
technocratization of values 252–4
Tengs, T.O. 90
thalidomide 303, 306–7, 311
Thatcher, Margaret 220
The System of Objects 496
theory failures 195
Thévenon, O. 437
think-tanks 494–5
Tilley, N. 102
Time to Change campaign 294, 295
timely (healthcare evaluation metric) 284
Titmuss, R. 203–4
‘tobacco wars’ 519
Tooley, J. 511
‘top-down’ approaches 423
Topping, K. 508
Towers, A.-M. 337
trade-offs 4, 75
and economic evaluation of policies 84, 87, 91, 93
and healthcare systems 287, 296–7
and long-term care policies 330–31, 336, 339
and performance management 234, 237
and public-sector reforms 456, 457, 459, 460, 462, 464, 469
and randomized controlled trials 29
trade unions 204, 205, 366, 389
Transforming Rehabilitation approach 265
transparency 116, 126, 130, 183, 184, 233, 289, 416, 519
TRASI (Tools and Resources for Assessing Social Impact) database 192
treatment effects 19, 28, 40–42, 43–5, 46–7, 48, 51, 53, 352–3
Trinder, L. 102
TRIPS (Trade-Related Aspects of Intellectual Property Rights) 318

M4175-GREVE_9781785363245
Downloaded from https://www.elgaronline.com/ at 11/01/2023 08:29:22AM
via free access
Trowler, P. 495

t-tests 28

tumour shrinkage 313

Twelve Outstanding Secondary Schools 511

Twenty Outstanding Primary Schools 511
two-communities model (of science/policy relationship) 145, 146–7

UC (Universal Credit) 369

UCTs (unconditional cash transfers) 164, 170–71
unconditional models 30–31
unemployment see employment/unemployment

UNICEF (United Nations Children’s Fund) 444

unintended consequences 431, 432, 433, 434–5, 437, 444, 448–9
universal benefits 432–3, 436–8, 475

Universal Declaration on Human Rights 175

University of Aarhus 505

‘unknown unknowns’ 85

Urban Institute 25

‘use’ value of consumer goods 496–7, 500, 501–2
‘use’/‘misuse’ of evaluation 162, 169–74, 177
‘use’/‘misuse’ of ‘evidence’ 242, 244–5, 252

useful data collection 194–5, 199

‘useful’ studies 116

use-inspired basic research 495–6

user fees 311

‘utilization’ of research 148

utilization-focused evaluations 187

Valentine, J.C. 34

validity (of QoL instruments) 332–3

value-based rationales 124–5, 126, 128

Van den Bergh, J. 87–8

Van Lancker, W. 436, 438

Van Mechelen, N. 436

VAT (value-added tax) 62

Veding, E. 461, 225

Veisten, K. 80

Verbst, G. 436, 438

vertical efficiency 483, 487–90

vertical equity 230

Viagra 308

Vining, A.R. 86

VLY (value of a life year) 89–90

voluntary health insurance 289

VSL (value of a statistical life) 83, 88, 89, 96

Walden Two 161–2, 177

Wallace, A. 108, 115

Wapler, R. 356

Warren, J. 215

washback effects 258–9

WCAs (Work Capability Assessments) 214–15, 216, 364–7, 377–9
appeals against 364, 371–4, 376, 378
and benefit sanctions 364, 366, 367, 368, 375

case studies 373–4

and Coalition government 364, 366, 367–70, 375, 378

and conditionality 364–5, 366, 367–8, 369–70, 373, 375
‘creaming’ and ‘parking’ 375–7
and evidence-based policy 366, 378
impact assessment 372–4
model of 370–75

and New Labour government 364, 365–6, 367–9, 375

points system 370–71, 373, 374

welfare to work programmes 364, 365, 368, 369–70, 372

Weiss, C. 147–8, 508

welcoming society 389, 391–2

welfare conditionality see conditionality
‘welfare quarantining’ 170, 174, 176

Welfare Reform Act (2009) 367, 368

Welfare State (UK) 203

and ‘activation’ policies 212, 213, 214, 215, 218–19

and austerity policies 203, 209–11, 213–14, 219

and citizenship rights 203–5, 218–19
continuing differences in 205–10
cross-national comparisons 203, 215–19
development of 203, 204–5

and neoliberalism 203, 204, 205–7, 210–11, 220
and new public management 203, 206
regional and local differences 207, 208, 212–15
and social rights 204–5, 207, 210, 219
welfare reform 210–12
Work Capability Assessments see WCAs
welfare to work programmes 168, 197–8, 364, 365, 368, 369–70, 372
‘welfare/benefit dependency’ 168, 346, 366
‘well-ordered science’ 125
Westergaard, M.K. 244
What Works Centre for Improving Education Outcomes for School-aged Children 504
What Works Clearinghouse 24
What Works Network 504
Whitty, G. 503
WHO (World Health Organization) 141, 142, 280–81
WHOQoL (QoL instrument) 334, 335, 336
Wimbush, E. 251–2
Wistow, J. 209
Wolfers, J. 346
Wollmann, H. 457
Work and Health Programme 379
Work and Pensions Select Committee 371, 372, 377
Work Choice 376
work conditionality see conditionality ‘work first’ policies 354, 364, 372
World Bank 164, 165, 231
World Food Programme (UN) 188
WP (Work Programme) 267, 272, 364, 368, 369–70, 375–6, 379
Wright, Sharon 172
WSIPP (Washington State Institute for Public Policy) 95
WT Grant Foundation 31
WTO (World Trade Organization) 318
Zaragoza indicators 386, 387–8, 389, 390–91